Psyadon's ecopipam meets Phase II Tourette's endpoint

Psyadon Pharmaceuticals Inc. (Germantown, Md.) said an interim analysis showed ecopipam met the primary endpoint of reducing Yale Global Tic Severity Score from baseline to week eight in the Phase II PSY301 trial to treat Tourette's syndrome. Psyadon subsequently stopped the open-label trial early. The analysis included 15 evaluable patients. The trial was designed to enroll about 25-30 patients. Ecopipam is a selective dopamine D1 receptor antagonist. ...